Challenges in the Management of Hemophilia B with Inhibitor

Abstract

Development of factor IX (FIX) inhibitor is a rare but challenging complication in hemophilia B. In addition to inefficacy of specific replacement therapy, FIX inhibitors increase morbidity due to serious allergic reactions/anaphylaxis upon treatment with FIX. Limited experience with immune tolerance induction (ITI) shows a high risk of nephrotic syndrome development and poor ITI outcomes. Recently, immunomodulation therapy has been used in ITI regimens in hemophilia B; however, relevant guidelines for ITI in hemophilia B are still lacking. We describe a 7-year-old hemophilia B patient with “null” mutation Arg29 stop who underwent surgery and massive transfusion therapy in the neonatal period and developed an FIX inhibitor after consecutive 20 exposures to FIX concentrate. At the age of 6 years, a high-dose ITI was commenced combined with immunomodulation therapy including rituximab, dexamethasone, and intravenous immunoglobulin. Allergic reactions that occurred in the third week of ITI were resolved by premedication with antihistamines and continued immunomodulation protocol without any need for ITI interruption. Inhibitor was negative from week 10; however, doses of FIX continued unchanged until pharmacokinetic criteria for success were met at month 9 of ITI. One year after the start of ITI, the patient started regular prophylaxis with FIX 41 IU/kg three times a week. No further allergic reactions or any signs of nephrotic syndrome have occurred.

Keywords

hemophilia B - FIX inhibitor - allergic reactions - immune tolerance induction - immunomodulation therapy - rituximab

• References

• 1 Astermark J, Lacroix-Desmazes S, Reding MT. Inhibitor development. Haemophilia 2008; 14 (Suppl. 03) 36-42
• 2 DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 (Suppl. 01) 1-22
• 3 DiMichele DM. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138 (3) 305-315
• 4 Puetz J, Soucie JM, Kempton CL, Monahan PE ; Hemophilia Treatment Center Network (HTCN) Investigators. Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database. Haemophilia 2013; (e-pub ahead of print). doi:10.1111/hae.12229
• 5 Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12 (Suppl. 06) 15-22
• 6 Coppola A, Margaglione M, Santagostino E , et al; AICE PROFIT Study Group. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7 (11) 1809-1815
• 7 Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009; 35 (8) 723-734
• 8 Coppola A, Santoro C, Tagliaferri A, Franchini M, DI Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia 2010; 16 (Suppl. 01) 13-19
• 9 Hay CR, DiMichele DM ; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119 (6) 1335-1344
• 10 Collins PW, Chalmers E, Hart DP , et al; UK Haemophilia Centre Doctors. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). Br J Haematol 2013; 160 (2) 153-170
• 11 Ewenstein BM, Takemoto C, Warrier I , et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89 (3) 1115-1116
• 12 DiMichele DM, Kroner BL ; North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87 (1) 52-57
• 13 Warrier I. Inhibitors in hemophilia B. In: Lee CA, Berntorp E, Hoots WK, , eds. Textbook of Hemophilia. Oxford and Malden, MA: Blackwell Publishing; 2005: 97-100
• 14 Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15 (5) 1027-1031
• 15 DiMichele DM. Immune tolerance in haemophilia: the long journey to the fork in the road. Br J Haematol 2012; 159 (2) 123-134
• 16 Dioun AF, Ewenstein BM, Geha RS, Schneider LC. IgE-mediated allergy and desensitization to factor IX in hemophilia B. J Allergy Clin Immunol 1998; 102 (1) 113-117
• 17 Shibata M, Shima M, Misu H, Okimoto Y, Giddings JC, Yoshioka A. Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia 2003; 9 (3) 269-271
• 18 Curry NS, Misbah SA, Giangrande PLF, Keeling DM. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction. Haemophilia 2007; 13 (3) 328-330
• 19 Chuansumrit A, Moonsup Y, Sirachainan N, Benjaponpitak S, Suebsangad A, Wongwerawattanakoon P. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate. Blood Coagul Fibrinolysis 2008; 19 (3) 208-211
• 20 Cross DC, Van Der Berg HM. Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. Haemophilia 2007; 13 (1) 111-114
• 21 Wermes C, von Depka Prondzinski M, Welte K, Sykora K-W. New strategy for the treatment of factor IX inhibitors in severe haemophilia B. Blood 2000; 96: 647 (abstract)
• 22 Klarmann D, Martinez Saguer I, Funk MB , et al. Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia 2008; 14 (1) 44-49
• 23 Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125 (3) 366-368
• 24 Alexander S, Hopewell S, Hunter S, Chouksey A. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. J Pediatr Hematol Oncol 2008; 30 (1) 93-95
• 25 Beutel K, Hauch H, Rischewski J, Kordes U, Schneppenheim J, Schneppenheim R. ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. Hamostaseologie 2009; 29 (2) 155-157
• 26 Barnes C, Davis A, Furmedge J, Egan B, Donnan L, Monagle P. Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX. Haemophilia 2010; 16 (5) 840-841
• 27 Thorland EC, Drost JB, Lusher JM , et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999; 5 (2) 101-105
• 28 Castaman G, Bonetti E, Messina M, Morfini M, Rocino A, Scaraggi FA, Tagariello G . and Italian Association of Hemophilia Centers. Inhibitors in haemophilia B: the Italian experience. Haemophilia 2013; (e-pub ahead of print). doi:10.1111/hae.12158
• 29 Sawamoto Y, Shima M, Yamamoto M , et al. Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thromb Res 1996; 83 (4) 279-286
• 30 Verghese P, Darrow S, Kurth MH, Reed RC, Kim Y, Kearney S. Successful management of factor IX inhibitor-associated nephrotic syndrome in a hemophilia B patient. Pediatr Nephrol 2013; 28 (5) 823-826
• 31 Nagel K, Laudenbach L, Rivard GE, Jardine L, Chan AK, Pai MK. Immune tolerance induction for a patient with factor IX inhibitors—a case report. Haemophilia 2011; 17 (2) 315
• 32 Klukowska A, Laguna P, Waleszkiewicz-Majewska B , et al. Successful immune tolerance induction in two boys with haemophilia B and inhibitory antibodies. Haemophilia 2012; 18 (3) e67-e69
• 33 Poon MC. Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIII. Haemophilia 2006; 12 (Suppl. 04) 61-69
• 34 Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002; 87 (3) 431-435